article thumbnail

European Congress on Advanced Treatments and Technologies in Skin & Aesthetics

Online Laser Training

Dr Godfrey Town gave a talk on ‘ Update on Home-Use Devices: New Devices, Regulations & Safety ’ as an Invited Speaker at the new European Congress on Advanced Treatments and Technologies in Skin & Aesthetics (Skin-Med2019) annual conference held 5th to 8th December 2019 at the Holton Munich City Hotel in Germany.

article thumbnail

European Congress on Advanced Treatments and Technologies in Skin & Aesthetics

Online Laser Training

Dr Godfrey Town gave a talk on ‘ Update on Home-Use Devices: New Devices, Regulations & Safety ’ as an Invited Speaker at the new European Congress on Advanced Treatments and Technologies in Skin & Aesthetics (Skin-Med2019) annual conference held 5th to 8th December 2019 at the Holton Munich City Hotel in Germany.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Review Study Aims to Refine Safety Profile of JAK Inhibitors in AD

The Dermatology Digest

The comprehensive safety analysis establishes evidence regarding the safety of systematic Janus kinase inhibitors in patients with atopic dermatitis. They reviewed the available safety data and analyzed the risk of 11 adverse events from 14 RCTs published between 2019 and 2022.

Safety 36
article thumbnail

Review Study Aims to Refine Safety Profile of JAK Inhibitors in AD

The Dermatology Digest

They reviewed the available safety data and analyzed the risk of 11 adverse events from 14 RCTs published between 2019 and 2022. The post Review Study Aims to Refine Safety Profile of JAK Inhibitors in AD appeared first on The Dermatology Digest.

Safety 36
article thumbnail

A Closer Look at IPL and Lasers

Aesthetics Exposed

To perform these treatments, it is important to get advanced training that includes light physics and safety. This article appeared in the March 2019 issue. Find more on this topic in the digital magazine.

article thumbnail

FDA, EMA Accept Galderma’s BLA for Nemolizumab for PN and AD

The Dermatology Digest

This follows its designation as a Breakthrough Therapy for the treatment of pruritus associated with prurigo nodularis, originally granted in December 2019 and reconfirmed in March 2023. Nemolizumab was generally well tolerated and its safety profile was similar to placebo across the OLYMPIA and ARCADIA clinical trial programs.

article thumbnail

A comment on the 2024 EWG Sunscreen Guide; Is EWG actively harming safe consumer sun protection?

The Eco Well Blog

prevention of skin cancer, UV induced hyperpigmentation, painful sunburn, melasma, etc) far outweigh any potential risks.Sunscreens have a long track record of safety and still, despite some of the scary media reporting on the recent FDA studies, are overwhelmingly supported to be safe and effective. Colantonio, S., Lin, X., & Beecker, J.